Navigation Links
Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals
Date:12/10/2008

rage 3.2 episodes of diarrhea annually. These children risk not only death but also long-term sequelae: impairment of growth, fitness, school performance, and cognitive function.

There are no anti-diarrheal drugs safe for children for adjunct use with oral rehydration therapy (ORT). It is believed that novel drugs that reverse the devastating fluid loss of diarrheal diseases will help reduce the burden of diarrheal diseases worldwide.

Vibrio cholerae is an intestinal infection which results in the abrupt loss of large volumes of electrolyte rich watery stools, leading to severe and rapidly progressing dehydration and shock. Cholera, identified and detailed from the beginning of recorded history, was initially endemic to the Indian sub-continent. The disease began spreading almost 200 years ago, and is now pandemic and persists primarily in the developing world. The bacteria spreads through contaminated water and food. Because outbreaks can become massive epidemics, it is a reportable disease and is listed as a category B bioterrorism agent/disease by the Department of Health and Human Services - Centers for Disease Control.

ABOUT NAPO

Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. Napo was founded in November 2001, and is based in California, USA with a subsidiary in Mumbai, India and offices in Boston, South San Francisco, and southern California.

Other than crofelemer, Napo's pipeline has an early clinical stage drug candidate, NP-500, for the treatment of Type II diabetes mellitus and metabolic syndrome and novel and proprietary anti-cancer agents in pre-clinical development. Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions. Napo has entered into two screening relationships associated with this collecti
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Mediaplanet has joined forces with Raw Elements ... importance of proper sun protection. The print component of ... circulation of approximately 250,000 copies and an estimated readership ... through a vast social media strategy, and across a ... explore the digital version of the campaign, click ...
(Date:5/29/2015)... Ca (PRWEB) May 29, 2015 ... pain consultations with specialists, physical therapy, and injections ... experiencing mid back and/or lower back pain, Healthpointe ... epidural injections for herniated discs, disc protrusions and ... . , Healthpointe’s team of renowned surgeons ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The ... giving patients a long-lasting impression on what modern dentistry ... VisitandCare.com is on a mission to revolutionize the perception ... with a high-class Wellness & Spa. , The ... world’s most successful medical tourism agencies and ...
(Date:5/29/2015)... MN (PRWEB) May 29, 2015 As ... Patio and Metro series outdoor saunas have increased in ... landscaping projects, and work at summer cottages. While ... piqued interest in summer projects a few weeks earlier ... suburban communities with smaller lot sizes tend to prefer ...
(Date:5/29/2015)... 29, 2015 Vulvodynia is defined as ... significant physical, sexual, and psychological distress. Women’s ... Vulvodynia. The actual diagnosis is often made on the ... realize that this problem can be very troublesome to ... these symptoms, they need to schedule and appointment with ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2
... Liberator Medical,Holdings, Inc. (OTC Bulletin Board: LBMH.OB) reported ... 2007 sales, which is thus far,the highest sales ... the Company,s ongoing continuous targeted advertising effort., ... our November,sales, we believe that in our first ...
... near crowded roadways face more than 50% risk of breathing ... Children with asthma who are exposed to traffic pollution are ... says a study that looked at children in the Mexican ... United States. , "Major cities along the northern and ...
... 13 The Ensign,Group, Inc. (Nasdaq: ENSG ... of,skilled nursing, rehabilitative care services and assisted living,companies, ... two skilled,nursing facilities in California and one assisted ... of approximately $12.8 million., (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ...
... part of its ongoing,global campaign to lower drug prices ... worldwide, AIDS Healthcare Foundation,(AHF) today responded to a modest ... Cipla, on three of its antiretroviral drugs to,fight HIV/AIDS. ... AHF-led,advocacy campaign aimed at pressuring Cipla to lower its ...
... in patients battling stomach cancer , , THURSDAY, Dec. 13 ... sunitinib (Sutent), which fights stomach tumors, can also create ... , All patients taking sunitinib, but especially those ... and treatment for high blood pressure and other signs ...
... Pro Bowler and TODAY,correspondent Tiki Barber spoke publicly for ... affects such a wide range of people in,different circumstances ... he told Meredith Vieira this morning on TODAY., ... founding,member and president, also appeared on TODAY to discuss ...
Cached Medicine News:Health News:Liberator Medical Supply Exceeds Projected November Sales 2Health News: Traffic Pollution Hurts Asthmatic Kids' Lungs 2Health News:The Ensign Group, Inc. Acquires Assets of Three Previously Leased Facilities 2Health News:Cipla Offers Modest AIDS Drug Price Cut: 'Not Nearly Enough,' says AHF 2Health News:Cipla Offers Modest AIDS Drug Price Cut: 'Not Nearly Enough,' says AHF 3Health News:New Cancer Drug Tied to Heart Problems 2Health News:New Cancer Drug Tied to Heart Problems 3Health News:New Cancer Drug Tied to Heart Problems 4Health News:Former NFL Star Tiki Barber and CURE Founder Susan Axelrod Speak Out About Epilepsy on TODAY Show 2
(Date:5/28/2015)... May 28, 2015  Eli Lilly and Company (NYSE: ... announced cash tender offer for up to $1.6 billion aggregate ... Holders of notes who tendered, and did not validly ... New York City time, on May 27, 2015 ... by Lilly, are eligible to receive the total consideration. The ...
(Date:5/28/2015)... 28, 2015  Maetrics ( http://maetrics.com ), a leading ... wrapped up a successful conference, "The cost of non-compliance -- ... today in Zurich . ... its Switzerland -based team, experts provided ... Technology field to an exclusive local audience. The event ...
(Date:5/28/2015)... -- This report analyzes the worldwide markets for Intraocular Lenses ... Standard Intraocular Lenses, and Premium Intraocular Lenses. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2World Intraocular Lenses Industry 2World Intraocular Lenses Industry 3World Intraocular Lenses Industry 4World Intraocular Lenses Industry 5World Intraocular Lenses Industry 6World Intraocular Lenses Industry 7World Intraocular Lenses Industry 8World Intraocular Lenses Industry 9World Intraocular Lenses Industry 10World Intraocular Lenses Industry 11World Intraocular Lenses Industry 12World Intraocular Lenses Industry 13World Intraocular Lenses Industry 14World Intraocular Lenses Industry 15World Intraocular Lenses Industry 16World Intraocular Lenses Industry 17World Intraocular Lenses Industry 18World Intraocular Lenses Industry 19World Intraocular Lenses Industry 20World Intraocular Lenses Industry 21World Intraocular Lenses Industry 22World Intraocular Lenses Industry 23World Intraocular Lenses Industry 24World Intraocular Lenses Industry 25World Intraocular Lenses Industry 26
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, announced data from a recently ... oral dose formulation for LX4211, a dual inhibitor of ... Results from the study demonstrated that administration of ...
... Jan. 5, 2011 The pharmaceutical industry,s steep ... strategy and development executives to uncover opportunities for ... combination therapies with branded products to extend patent ... products can extend a therapeutic advantage and become ...
Cached Medicine Technology:Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 2Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 3Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 4Report Highlights Successful Strategies for Bringing FDC Products to Market 2
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-2000...
Prolactin EIA Reproductive Markers 025-BC-1037...
... (17aOHP) is produced by both the ... has relatively little progestational activity, it ... it is the,immediate precursor to 11-desoxycortisol ... 21-hydroxylation of 17aOHP,measurement of 17aOHP is ...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: